Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $88.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 26.31% year-over-year to $88.5 million, compared with a TTM value of $483.7 million through Dec 2025, up 22.38%, and an annual FY2025 reading of $88.5 million, up 26.31% over the prior year.
  • Liabilities and Shareholders Equity was $88.5 million for Q4 2025 at Aligos Therapeutics, down from $109.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $263.1 million in Q3 2021 and bottomed at $70.1 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $149.6 million, with a median of $140.7 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 53.74% in 2024, then grew 26.31% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $235.4 million in 2021, then crashed by 37.68% to $146.7 million in 2022, then grew by 3.3% to $151.5 million in 2023, then plummeted by 53.74% to $70.1 million in 2024, then increased by 26.31% to $88.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ALGS at $88.5 million in Q4 2025, $109.8 million in Q3 2025, and $134.7 million in Q2 2025.